Structures by: Filinchuk Y.
Total: 126
C90H48B6Cl12N12O12
C90H48B6Cl12N12O12
Chemical Science (2011) 2, 9 1719
a=13.4133(9)Å b=13.4133(9)Å c=92.656(12)Å
α=90.00° β=90.00° γ=120.00°
C114H60B6Cl12N12O12
C114H60B6Cl12N12O12
Chemical Science (2011) 2, 9 1719
a=14.3139(9)Å b=14.3139(9)Å c=30.848(2)Å
α=90.00° β=90.00° γ=120.00°
C108H60B6Cl12N12O12
C108H60B6Cl12N12O12
Chemical Science (2011) 2, 9 1719
a=13.5162(6)Å b=13.5162(6)Å c=93.155(5)Å
α=90.00° β=90.00° γ=120.00°
C144H84B6Cl12N12O12
C144H84B6Cl12N12O12
Chemical Science (2011) 2, 9 1719
a=13.5417(3)Å b=13.5417(3)Å c=118.223(7)Å
α=90.00° β=90.00° γ=120.00°
B3H12KZn
B3H12KZn
The Journal of Physical Chemistry C (2012) 116, 1 1563
a=7.6291(8)Å b=7.6291(8)Å c=10.977(2)Å
α=90.00000° β=90.00000° γ=120.00000°
B1.89Cl2.11H16K2Zn
B1.89Cl2.11H16K2Zn
The Journal of Physical Chemistry C (2012) 116, 1 1563
a=12.3628(38)Å b=9.1099(25)Å c=7.3394(24)Å
α=90° β=95.737(24)° γ=90°
BH4Li
BH4Li
Journal of Physical Chemistry C (2008) 112, 28 10579
a=4.3228(10)Å b=4.3228(10)Å c=7.0368(10)Å
α=90.00° β=90.00° γ=120.00°
BH4Li
BH4Li
Journal of Physical Chemistry C (2008) 112, 28 10579
a=7.141(5)Å b=4.431(3)Å c=6.748(4)Å
α=90.00° β=90.00° γ=90.00°
C20H15ClN2O5
C20H15ClN2O5
Journal of medicinal chemistry (2008) 51, 7 2227-2243
a=5.3438(3)Å b=10.7546(6)Å c=32.137(3)Å
α=90.00000° β=90.00000° γ=90.00000°
C20H14ClFN2O5
C20H14ClFN2O5
Journal of medicinal chemistry (2008) 51, 7 2227-2243
a=5.32926(7)Å b=10.77905(18)Å c=31.3253(5)Å
α=90.00° β=90.00° γ=90.00°
Ce (Mn1.8 Al0.2) D4.36
Al0.2CeD4.36Mn1.8
Journal of Alloys Compd. (2003) 356, 673-678
a=5.9788Å b=5.9788Å c=9.76Å
α=90° β=90° γ=120°
Ce (Mn1.8 Al0.2) D3.3
Al0.2CeD3.3Mn1.8
Journal of Alloys Compd. (2003) 356, 673-678
a=5.9353Å b=5.9353Å c=9.7641Å
α=90° β=90° γ=120°
Mo1.282 O (P2 O7)
Mo1.282O8P2
Journal of Alloys Compd. (2003) 360, 81-84
a=22.88Å b=22.94Å c=4.83Å
α=90° β=90° γ=90.36°
C19H16ClN2O3PS
C19H16ClN2O3PS
New J. Chem. (2016) 40, 2 1230
a=17.7272(3)Å b=10.9714(2)Å c=10.2468(2)Å
α=90° β=97.6257(19)° γ=90°
C6H7ClN,CNS
C6H7ClN,CNS
New J. Chem. (2016) 40, 2 1230
a=15.742(4)Å b=7.7102(9)Å c=7.0694(12)Å
α=90° β=99.36(2)° γ=90°
C12H10O4P,C6H7ClN,0.5(C6H6)
C12H10O4P,C6H7ClN,0.5(C6H6)
New J. Chem. (2016) 40, 2 1230
a=6.7856(6)Å b=11.797(5)Å c=15.113(4)Å
α=67.80(3)° β=80.388(17)° γ=74.82(2)°
C13H15ClN2S
C13H15ClN2S
New J. Chem. (2016) 40, 2 1230
a=8.4353(4)Å b=14.9782(9)Å c=11.5168(8)Å
α=90° β=104.453(6)° γ=90°
C34H27BrCuN2P
C34H27BrCuN2P
New J. Chem. (2016) 40, 7 6156
a=9.5272(3)Å b=18.5794(6)Å c=32.0159(14)Å
α=90° β=90° γ=90°
C34H27ClCuN2P
C34H27ClCuN2P
New J. Chem. (2016) 40, 7 6156
a=16.837(2)Å b=19.0230(16)Å c=19.862(3)Å
α=115.622(11)° β=101.572(12)° γ=90.310(9)°
RS-naproxen D-proline 1:1 cocrystal, polymorph I
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.1578(5)Å b=5.8278(2)Å c=25.6828(14)Å
α=90° β=98.762(5)° γ=90°
S-naproxen L-proline 1:1 cocrystal, polymorph II
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=16.2991(7)Å b=5.8654(3)Å c=18.6876(9)Å
α=90° β=100.052(4)° γ=90°
RS-naproxen DL-proline 1:1 cocrystal, polymorph I
C14H14O3,C5H9NO2
CrystEngComm (2018) 20, 45 7308
a=9.9964(3)Å b=9.0958(4)Å c=39.9654(15)Å
α=90° β=90° γ=90°
RS-naproxen D-proline 1:1 cocrystal, polymorph II
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.5901(6)Å b=5.7587(3)Å c=51.425(3)Å
α=90° β=90° γ=90°
RS-naproxen L-proline 1:1 cocrystal, polymorph III
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.705(2)Å b=5.7631(8)Å c=25.000(5)Å
α=90° β=95.041(11)° γ=90°
S-naproxen ethanol solvate
C14H14O3,C2H6O
CrystEngComm (2018) 20, 45 7308
a=5.9273(2)Å b=8.7713(5)Å c=28.0747(15)Å
α=90° β=90° γ=90°
1:1 RS-naproxen D-proline cocrystal methanol solvate
2(C14H14O3),2(C5H9NO2),CH4O
CrystEngComm (2018) 20, 45 7308
a=12.9532(4)Å b=5.76337(15)Å c=25.2764(6)Å
α=90° β=93.984(3)° γ=90°
S-naproxen DL-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.8836(7)Å b=9.0952(18)Å c=44.047(10)Å
α=90° β=90° γ=90°
S-naproxen DL-proline 1:1 cocrystal
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=8.84337(19)Å b=5.83510(15)Å c=33.6766(7)Å
α=90° β=91.9839(19)° γ=90°
RS-naproxen DL-proline 1:1 cocrystal, polymorph II
C14H14O3,C5H9NO2
CrystEngComm (2018) 20, 45 7308
a=34.537(4)Å b=9.0077(8)Å c=5.7183(5)Å
α=90° β=90° γ=90°
1:1 S-naproxen DL-proline cocrystal hydrate
2(C14H14O3),2(C5H9NO2),2(H2O1)
CrystEngComm (2018) 20, 45 7308
a=6.06468(13)Å b=12.2629(3)Å c=50.6290(15)Å
α=90° β=90° γ=90°
S-naproxen L-proline 2:3 cocrystal
2(C14H14O3),3(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.70180(10)Å b=18.8609(3)Å c=37.2392(5)Å
α=90° β=90° γ=90°
S-naproxen L-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.88160(7)Å b=8.79809(10)Å c=45.4679(5)Å
α=90° β=90° γ=90°
C15H9AgN9,ClO4
C15H9AgN9,ClO4
Chem.Commun. (2015) 51, 9547
a=20.2313(6)Å b=20.2313(6)Å c=20.2313(6)Å
α=90° β=90° γ=90°
C40H27Ag4F12N27O12S4
C40H27Ag4F12N27O12S4
Chem.Commun. (2015) 51, 9547
a=10.6023(8)Å b=18.0069(15)Å c=33.316(3)Å
α=90° β=90.1374(16)° γ=90°
C24H18Ag2F12N18P2
C24H18Ag2F12N18P2
Chem.Commun. (2015) 51, 9547
a=10.6565(7)Å b=16.8754(11)Å c=19.1418(13)Å
α=90° β=90° γ=90°
RS-naproxen L-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.84172(9)Å b=8.98394(13)Å c=45.6816(8)Å
α=90° β=90° γ=90°
C26H22N2O4
C26H22N2O4
CrystEngComm (2016) 18, 38 7249
a=14.0292(9)Å b=5.0669(4)Å c=14.7229(11)Å
α=90° β=99.433(7)° γ=90°
C26H22N2O4
C26H22N2O4
CrystEngComm (2016) 18, 38 7249
a=6.7362(6)Å b=24.2039(15)Å c=6.8686(5)Å
α=90.00° β=112.293(9)° γ=90.00°
Triammine Calcium Dodecahydro-closo-dodecaborate
B12H122,3(H3N),Ca2
Dalton Trans. (2017)
a=11.86978(18)Å b=11.86978(18)Å c=16.7977(5)Å
α=90.00000° β=90.00000° γ=120.00000°
Tetraammine Dilithium Dodecahydro-closo-dodecaborate
B12H122,4(H3N),2(Li1)
Dalton Trans. (2017)
a=8.4122(3)Å b=9.5193(5)Å c=9.6434(5)Å
α=90.00000° β=99.472(4)° γ=90.00000°
Tetraammine Disodium Dodecahydro-closo-dodecaborate
B12H122,4(H3N),2(Na1)
Dalton Trans. (2017)
a=8.6875(2)Å b=9.4168(3)Å c=9.9096(3)Å
α=90.00000° β=98.3296(18)° γ=90.00000°
Lithium Sodium diamidoborane
2(BH5N),Na,Li
Dalton transactions (Cambridge, England : 2003) (2011) 40, 17 4407-4413
a=5.0197(4)Å b=7.1203(7)Å c=8.9198(9)Å
α=103.003(6)° β=102.200(5)° γ=103.575(5)°
C16H36N2O4P2S2
C16H36N2O4P2S2
Dalton transactions (Cambridge, England : 2003) (2013) 42, 15 5532-5538
a=17.7793(5)Å b=7.9981(2)Å c=17.2729(6)Å
α=90.00° β=91.163(3)° γ=90.00°
C36H72Co2N8O8P4S8
C36H72Co2N8O8P4S8
Dalton transactions (Cambridge, England : 2003) (2013) 42, 15 5532-5538
a=10.2715(14)Å b=10.7122(13)Å c=14.188(3)Å
α=91.162(13)° β=92.255(14)° γ=101.349(11)°
C184H142N2O32U6
C184H142N2O32U6
Chemical communications (Cambridge, England) (2010) 46, 16 2757-2759
a=18.2263(6)Å b=18.9950(10)Å c=26.5602(7)Å
α=75.858(3)° β=79.099(2)° γ=64.725(4)°
C191.5H151.5N1.5O32U6
C191.5H151.5N1.5O32U6
Chemical communications (Cambridge, England) (2010) 46, 16 2757-2759
a=18.707(2)Å b=19.412(2)Å c=26.547(3)Å
α=74.677(2)° β=77.944(2)° γ=63.905(2)°
C96H160ClN20O61.5Tb4
C96H160ClN20O61.5Tb4
Chemical communications (Cambridge, England) (2008) 29 3378-3380
a=30.5311(5)Å b=33.6509(3)Å c=27.1283(3)Å
α=90.00° β=98.1160(10)° γ=90.00°
C40.5H62.5KN3O4U
C40.5H62.5KN3O4U
Chemical communications (Cambridge, England) (2009) 34, 14 1843-1845
a=11.7846(3)Å b=30.2442(5)Å c=13.0298(3)Å
α=90.00° β=102.368(2)° γ=90.00°
C40.5H62.5N3O4U
C40.5H62.5N3O4U
Chemical communications (Cambridge, England) (2009) 34, 14 1843-1845
a=19.6726(6)Å b=20.0780(6)Å c=11.4096(3)Å
α=90.00° β=101.116(3)° γ=90.00°
?
B4Ca3D12O3
Journal of Materials Chemistry (2011) 21, 20 7188
a=8.99810(24)Å b=8.05617(21)Å c=11.76780(26)Å
α=90.0° β=90.0° γ=90.0°
S-naproxen L-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.05836(11)Å b=7.1121(3)Å c=45.2723(17)Å
α=90° β=90° γ=90°
S-naproxen D-tryptophan monohydrate
C14H14O3,C11H12N2O2,H2O
CrystEngComm (2014) 16, 35 8185
a=5.88418(16)Å b=11.3844(3)Å c=34.6863(9)Å
α=90° β=90° γ=90°
S-naproxen D-tyrosine
C14H14O3,C9H11NO3
CrystEngComm (2014) 16, 35 8185
a=9.4508(4)Å b=5.9725(2)Å c=18.9525(7)Å
α=90.00000° β=103.814(2)° γ=90.00000°
TPymT
C15H9N9
CrystEngComm (2015) 17, 10 2190
a=10.42385(17)Å b=10.42385(17)Å c=21.7533(2)Å
α=90.00000° β=90.00000° γ=120.00000°
Pyrimidine-2-carboximidamide
C5H6N4
CrystEngComm (2015) 17, 10 2190
a=5.55795(14)Å b=7.25941(12)Å c=7.7260(2)Å
α=84.431(2)° β=71.913(3)° γ=80.163(2)°
TPymT
C15H9N9
CrystEngComm (2015) 17, 10 2190
a=10.4339(10)Å b=10.4339(10)Å c=21.467(2)Å
α=90° β=90° γ=120°
2-cyanopyrimidine
C5H3N3
CrystEngComm (2015) 17, 10 2190
a=3.97105(6)Å b=8.12770(14)Å c=16.0709(3)Å
α=90.00000° β=90.00000° γ=90.00000°
S-naproxen L-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.05836(11)Å b=7.1121(3)Å c=45.2723(17)Å
α=90° β=90° γ=90°
S-naproxen D-alanine
C14H14O3,C3H7NO2
CrystEngComm (2014) 16, 35 8185
a=5.3366(4)Å b=6.9013(6)Å c=44.227(4)Å
α=90° β=90° γ=90°
S-naproxen D-tryptophan monohydrate
C14H14O3,C11H12N2O2,H2O
CrystEngComm (2014) 16, 35 8185
a=5.88418(16)Å b=11.3844(3)Å c=34.6863(9)Å
α=90° β=90° γ=90°
S-naproxen D-tyrosine
C14H14O3,C9H11NO3
CrystEngComm (2014) 16, 35 8185
a=9.4508(4)Å b=5.9725(2)Å c=18.9525(7)Å
α=90.00000° β=103.814(2)° γ=90.00000°
Sodium dimanganese pentaborohydride bis(diethyl ether)
C8H40B5Mn2NaO2
Dalton transactions (Cambridge, England : 2003) (2015) 44, 14 6571-6580
a=14.5133(6)Å b=7.4487(3)Å c=10.7119(5)Å
α=90° β=104.338(5)° γ=90°
Manganese bisborohydride tris(pyridine)
C15H23B2MnN3
Dalton transactions (Cambridge, England : 2003) (2015) 44, 14 6571-6580
a=12.3618(4)Å b=15.5064(5)Å c=9.2859(4)Å
α=90° β=101.126(4)° γ=90°
Lithium dimanganese pentaborohydride bis(diethyl ether)
B5H20Mn2,2(C4H10O),Li
Dalton transactions (Cambridge, England : 2003) (2015) 44, 14 6571-6580
a=21.7106(3)Å b=7.72944(12)Å c=14.02422(19)Å
α=90.00000° β=110.8649(14)° γ=90.00000°
5-phenyl-2-(2-pyridyl)pyridine
2(C8H6N),C8H6N1
Dalton transactions (Cambridge, England : 2003) (2015) 44, 38 16824-16832
a=5.6180(10)Å b=15.682(3)Å c=19.716(3)Å
α=90° β=91.990(2)° γ=90°
C52H42CuN2P2,BF4
C52H42CuN2P2,BF4
Dalton transactions (Cambridge, England : 2003) (2015) 44, 38 16824-16832
a=10.5921(4)Å b=13.9695(6)Å c=15.0293(5)Å
α=90° β=94.299(3)° γ=90°
C34H27CuIN2P
C34H27CuIN2P
Dalton transactions (Cambridge, England : 2003) (2015) 44, 38 16824-16832
a=9.3666(3)Å b=10.2614(3)Å c=30.1047(11)Å
α=90° β=93.907(3)° γ=90°
Tl2Te
Tl2Te
Acta Crystallographica Section C (2002) 58, 5 i63-i65
a=15.6621(9)Å b=8.9873(4)Å c=31.196(2)Å
α=90° β=100.761(7)° γ=90°
Δ-manganese borohydride
Mn2,(BH41)2
Chemistry of Materials (2016) 28, 1 274
a=5.55260(5)Å b=5.55260(5)Å c=6.07271(8)Å
α=90.00000° β=90.00000° γ=90.00000°
Δ-manganese borohydride
Mn2,(BH41)2
Chemistry of Materials (2016) 28, 1 274
a=7.85254(6)Å b=7.85254(6)Å c=12.14548(17)Å
α=90.00000° β=90.00000° γ=90.00000°
Δ-manganese borohydride
Mn2,(BH41)2
Chemistry of Materials (2016) 28, 1 274
a=12.638(15)Å b=9.321(10)Å c=9.205(17)Å
α=90.00000° β=90.00000° γ=90.00000°
B2H8Mg
B2H8Mg
Chemistry of Materials (2009) 21, 5 925
a=10.3540(12)Å b=10.3540(12)Å c=37.055(4)Å
α=90.00° β=90.00° γ=120.00°
AlB4H18N
AlB4H18N
Chemistry of Materials (2015) 27, 3 768
a=7.8585(2)Å b=6.86473(14)Å c=15.7136(8)Å
α=90° β=96.429(4)° γ=90°
Magnesium borohydride
0.02(Kr),2(BH4),Mg
ACS applied materials & interfaces (2020)
a=15.6782(13)Å b=15.6782(13)Å c=15.6782(13)Å
α=90.0000° β=90.0000° γ=90.0000°
Magnesium borohydride
0.008(Kr),2(BH4),Mg
ACS applied materials & interfaces (2020)
a=15.7779(3)Å b=15.7779(3)Å c=15.7779(3)Å
α=90.0000° β=90.0000° γ=90.0000°
Magnesium borohydride
0.404(Kr),2(BH4),Mg
ACS applied materials & interfaces (2020)
a=15.7621(2)Å b=15.7621(2)Å c=15.7621(2)Å
α=90.0000° β=90.0000° γ=90.0000°
Magnesium borohydride
B2H8Kr0.557,Mg
ACS applied materials & interfaces (2020)
a=15.562(2)Å b=15.562(2)Å c=15.562(2)Å
α=90.00000° β=90.00000° γ=90.00000°
Magnesium borohydride
B2H8Kr0.635,Mg
ACS applied materials & interfaces (2020)
a=15.72748(11)Å b=15.72748(11)Å c=15.72748(11)Å
α=90.00000° β=90.00000° γ=90.00000°
Magnesium borohydride
0.313(Kr),2(BH4),Mg
ACS applied materials & interfaces (2020)
a=15.6109(18)Å b=15.6109(18)Å c=15.6109(18)Å
α=90.0000° β=90.0000° γ=90.0000°
C8H14N2O2,C6H10O4
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=12.9082(9)Å b=11.5417(8)Å c=12.5179(9)Å
α=90.00° β=116.342(9)° γ=90.00°
Levetiracetam 2,2-dimethylsuccinic acid cocrystal
C8H14N2O2,C6H10O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.23877(7)Å b=11.55362(12)Å c=11.34360(12)Å
α=90.00000° β=90.9259(9)° γ=90.00000°
C8H14N2O2,C7H6O4
C8H14N2O2,C7H6O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.2828(3)Å b=13.3843(6)Å c=18.7984(8)Å
α=90.00° β=96.638(4)° γ=90.00°
Etiracetam 2,4-dihydroxybenzoic acid cocrystal
C8H14N2O2,C7H6O4
Crystal Growth & Design (2014) 14, 6 2880
a=6.60584(3)Å b=13.11919(7)Å c=18.80723(8)Å
α=90.00000° β=90.00000° γ=90.00000°
C8H14N2O2,C7H5NO4
C8H14N2O2,C7H5NO4
Crystal Growth & Design (2014) 14, 6 2880
a=5.8455(2)Å b=11.6845(12)Å c=12.5762(10)Å
α=78.856(8)° β=82.443(6)° γ=84.035(7)°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=8.0511(4)Å b=13.0536(6)Å c=23.0243(9)Å
α=90.00° β=90.00° γ=90.00°
C8H14N2O2,2(C7H5NO4)
C8H14N2O2,2(C7H5NO4)
Crystal Growth & Design (2014) 14, 6 2880
a=24.2697(8)Å b=7.4683(2)Å c=13.3230(5)Å
α=90.00° β=104.663(4)° γ=90.00°
2(C7H5NO4),C8H14N2O2
2(C7H5NO4),C8H14N2O2
Crystal Growth & Design (2014) 14, 6 2880
a=7.0988(9)Å b=7.3613(10)Å c=12.1428(13)Å
α=77.496(10)° β=88.250(10)° γ=74.232(12)°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7253(2)Å b=20.2528(7)Å c=10.9457(5)Å
α=90.00° β=100.085(4)° γ=90.00°
C8H14N2O2,C2H2O4
C8H14N2O2,C2H2O4
Crystal Growth & Design (2014) 14, 6 2880
a=5.7646(4)Å b=19.8963(14)Å c=11.0690(8)Å
α=90.00° β=99.331(6)° γ=90.00°
C8H9N3O
C8H9N3O
The Journal of organic chemistry (2017) 82, 3 1666-1675
a=11.9213(6)Å b=4.6621(2)Å c=15.1386(7)Å
α=90° β=104.387(5)° γ=90°
C15H13N3O2
C15H13N3O2
The Journal of organic chemistry (2017) 82, 3 1666-1675
a=13.9167(3)Å b=14.5107(3)Å c=6.79621(18)Å
α=90° β=90° γ=90°
C11H13N3O
C11H13N3O
The Journal of organic chemistry (2017) 82, 3 1666-1675
a=5.9648(3)Å b=34.2029(15)Å c=10.1737(6)Å
α=90° β=91.052(5)° γ=90°
C14H12N4O
C14H12N4O
The Journal of organic chemistry (2017) 82, 3 1666-1675
a=5.8539(6)Å b=27.248(2)Å c=15.506(3)Å
α=90° β=100.049(13)° γ=90°
C14H10N4
C14H10N4
The Journal of organic chemistry (2017) 82, 3 1666-1675
a=30.257(2)Å b=6.1188(4)Å c=18.0108(13)Å
α=90° β=90° γ=90°
C16H15N3O
C16H15N3O
The Journal of organic chemistry (2017) 82, 3 1666-1675
a=13.9058(9)Å b=15.9471(7)Å c=14.5652(12)Å
α=90° β=115.575(9)° γ=90°
C8H4ClFeO5
C8H4ClFeO5
Journal of the American Chemical Society (2010) 132, 1127-1136
a=18.40(2)Å b=6.935(7)Å c=11.075(11)Å
α=90.00° β=90.00° γ=90.00°
C8H5FeO7
C8H5FeO7
Journal of the American Chemical Society (2010) 132, 1127-1136
a=17.841(4)Å b=6.8729(15)Å c=11.839(3)Å
α=90.00° β=90.00° γ=90.00°
MIL-88B(2OH)
C48H38Fe6O44
Journal of the American Chemical Society (2011) 133, 17839-17847
a=11.0910(16)Å b=11.0910(16)Å c=19.364(4)Å
α=90.00° β=90.00° γ=120.00°